albireo
reports
financial
results
provides
business
update
positive
phase
data
odevixibat
pfic
filings
track
later
early
phase
pfic
data
accepted
late
breakers
upcoming
aasld
meeting
introduces
new
novel
bile
acid
modulator
aasld
raised
million
gross
proceeds
public
offering
shares
company
host
business
update
call
tuesday
november
boston
globe
newswire
albireo
pharma
nasdaq
albo
rare
liver
disease
company
developing
novel
bile
acid
modulators
today
provided
business
update
reported
financial
results
third
quarter
ended
september
great
excitement
around
positive
data
late
breaker
acceptance
pedfic
largest
global
phase
clinical
trial
pfic
said
ron
cooper
president
chief
executive
officer
albireo
moving
new
stage
albireo
anticipating
regulatory
approval
priority
review
voucher
issuance
launch
second
half
next
year
deepening
pipeline
phase
trials
biliary
atresia
alagille
syndrome
advancing
adult
liver
recent
upcoming
highlights
odevixibat
achieved
high
statistical
significance
eu
primary
endpoints
pedfic
largest
ever
global
phase
clinical
trial
evaluating
efficacy
safety
odevixibat
study
demonstrated
sustained
reductions
bile
acids
pruritus
improved
growth
parameters
well
tolerated
low
incidence
diarrhea
children
positive
results
trial
announced
september
news
release
albireo
phase
trial
meets
primary
endpoints
odevixibat
pfic
track
complete
regulatory
filings
eu
later
early
anticipation
potential
regulatory
approval
issuance
rare
pediatric
disease
priority
review
voucher
launch
odevixibat
second
half
announced
acceptances
american
association
study
liver
diseases
aasld
liver
meeting
digital
tlmdx
held
november
news
release
albireo
odevixibat
pfic
phase
results
accepted
aasld
full
data
set
pedfic
trial
presented
also
late
breaker
poster
session
interim
results
pedfic
phase
extension
study
efficacy
safety
odevixibat
children
pfic
bold
second
phase
trial
odevixibat
continues
activate
new
sites
enroll
patients
despite
challenges
biliary
atresia
common
pediatric
cholestatic
liver
disease
number
one
cause
liver
transplantation
children
track
initiate
third
phase
trial
odevixibat
alagille
syndrome
end
early
stage
pipeline
preclinical
development
programs
progressing
adult
liver
disease
company
expects
complete
studies
new
lead
preclinical
candidate
year
company
present
adult
liver
disease
data
upcoming
aasld
meeting
november
news
release
albireo
odevixibat
pfic
phase
results
accepted
aasld
corporate
completed
underwritten
public
offering
shares
common
stock
price
per
share
net
proceeds
offering
approximately
million
deducting
underwriting
discounts
commissions
offering
expenses
despite
global
pandemic
albireo
continues
progress
clinical
programs
commercial
planning
monitoring
situation
closely
anticipation
product
filings
approvals
launch
following
aasld
meeting
albireo
host
investor
call
november
present
highlights
company
odevixibat
pedfic
pedfic
data
presentations
company
also
highlight
data
novel
bile
acid
modulator
approaches
new
product
candidate
adult
liver
diseases
third
quarter
financial
results
revenues
million
third
quarter
compared
million
third
quarter
higher
revenue
due
estimated
royalty
revenue
received
ea
pharma
elobixibat
treatment
chronic
constipation
royalty
revenue
passed
healthcare
royalty
partners
r
expenses
million
third
quarter
compared
million
third
quarter
higher
expenses
primarily
due
personnel
expenses
company
continues
increase
headcount
well
program
expenses
related
odevixibat
company
prepares
regulatory
filings
continues
develop
additional
indications
lead
asset
continued
advancement
preclinical
programs
also
contributed
higher
program
expenses
g
expenses
million
third
quarter
compared
million
third
quarter
increase
attributable
personnel
related
expenses
company
continues
increase
headcount
commercialization
readiness
expenses
net
loss
third
quarter
million
per
share
compared
million
per
share
third
quarter
company
cash
cash
equivalents
september
million
third
quarter
additional
million
net
proceeds
received
recently
completed
public
financings
deducting
underwriting
discounts
commissions
offering
expenses
result
cash
cash
equivalents
anticipated
sufficient
fully
fund
launches
odevixibat
revenue
generating
phase
albireo
virtual
business
update
call
albireo
host
event
tuesday
november
et
access
live
conference
call
phone
dial
domestic
international
provide
access
code
live
audio
webcast
accessible
media
investors
page
albireo
website
http
ensure
timely
connection
webcast
recommended
participants
register
least
minutes
prior
scheduled
start
time
archived
version
business
update
webcast
available
replay
events
presentations
section
media
investors
page
albireo
website
months
following
event
odevixibat
odevixibat
investigational
product
candidate
developed
treat
rare
pediatric
cholestatic
liver
diseases
including
progressive
familial
intrahepatic
cholestasis
pfic
biliary
atresia
alagille
syndrome
highly
potent
ileal
bile
acid
transport
inhibitor
ibati
odevixibat
acts
locally
small
intestine
odevixibat
require
refrigeration
taken
capsule
older
children
opened
sprinkled
onto
food
factors
key
importance
adherence
pediatric
patient
population
company
announced
positive
results
phase
pedfic
trial
odevixibat
september
odevixibat
currently
evaluated
ongoing
pedfic
trial
patients
pfic
bold
phase
trial
patients
biliary
atresia
initiation
pivotal
phase
trial
odevixibat
alagille
syndrome
also
anticipated
end
odevixibat
received
fast
track
rare
pediatric
disease
orphan
drug
designations
united
states
addition
fda
granted
orphan
drug
designation
odevixibat
treatment
alagille
syndrome
biliary
atresia
primary
biliary
cholangitis
ema
granted
odevixibat
orphan
designation
well
access
priority
medicines
prime
scheme
treatment
pfic
pediatric
committee
agreed
albireo
odevixibat
pediatric
investigation
plan
pfic
biliary
atresia
ema
also
granted
orphan
designation
odevixibat
treatment
alagille
syndrome
biliary
atresia
primary
biliary
cholangitis
odevixibat
potential
become
first
approved
drug
treatment
patients
pfic
company
intends
complete
regulatory
filings
eu
odevixibat
pfic
later
early
anticipation
potential
regulatory
approval
issuance
rare
pediatric
disease
priority
review
voucher
launch
second
half
albireo
albireo
pharma
biopharmaceutical
company
focused
development
novel
bile
acid
modulators
treat
rare
pediatric
adult
liver
diseases
adult
liver
diseases
disorders
albireo
lead
product
candidate
odevixibat
developed
treat
rare
pediatric
cholestatic
liver
diseases
phase
development
progressive
familial
intrahepatic
cholestasis
pfic
biliary
atresia
third
phase
trial
planned
alagille
syndrome
company
expects
complete
studies
new
preclinical
candidate
year
albireo
spun
astrazeneca
headquartered
boston
massachusetts
key
operating
subsidiary
gothenburg
sweden
boston
business
journal
named
albireo
one
best
places
work
massachusetts
second
consecutive
year
information
albireo
please
visit
statements
press
release
includes
statements
within
meaning
private
securities
litigation
reform
act
statements
include
statements
statements
historical
fact
regarding
among
things
plans
progress
scope
cost
initiation
duration
enrollment
results
timing
availability
results
development
odevixibat
albireo
product
candidate
program
including
regarding
expectations
regarding
impact
business
ability
adapt
approach
appropriate
phase
clinical
program
odevixibat
patients
pfic
pivotal
trial
odevixibat
biliary
atresia
bold
planned
pivotal
trial
odevixibat
alagille
syndrome
target
indication
development
approval
size
design
population
location
conduct
cost
objective
enrollment
duration
endpoints
clinical
trial
timing
initiation
completion
availability
reporting
results
clinical
trial
including
extension
study
odevixibat
pfic
pivotal
trial
odevixibat
biliary
atresia
planned
pivotal
trial
odevixibat
alagille
syndrome
potential
approval
commercialization
odevixibat
discussions
fda
ema
regarding
programs
potential
benefits
competitive
position
odevixibat
elobixibat
albireo
product
candidate
program
commercial
opportunity
target
indication
potential
effects
odevixibat
treatment
pfic
patients
potential
improve
current
standard
care
potential
benefits
orphan
drug
designation
potential
issuance
rare
pediatric
disease
priority
review
voucher
period
albireo
cash
resources
sufficient
fund
operating
requirements
runway
albireo
plans
expectations
future
operations
financial
position
revenues
costs
expenses
albireo
often
uses
words
anticipates
believes
plans
expects
projects
future
intends
may
could
estimates
predicts
potential
planned
continue
guidance
similar
expressions
identify
statements
actual
results
performance
experience
may
differ
materially
expressed
implied
statement
result
various
risks
uncertainties
factors
including
limited
negative
impacts
pandemic
including
manufacturing
supply
conduct
initiation
clinical
trials
aspects
business
whether
favorable
findings
clinical
trials
odevixibat
date
including
findings
indications
pfic
predictive
results
clinical
trials
odevixibat
whether
either
fda
ema
determine
primary
endpoint
respective
evaluations
treatment
duration
phase
trial
patients
pfic
sufficient
support
approval
odevixibat
united
states
european
union
treat
pfic
symptom
pfic
specific
pfic
subtype
otherwise
outcome
interpretation
regulatory
authorities
ongoing
study
pooling
analyzing
pfic
patient
data
timing
initiation
completion
availability
data
clinical
trials
odevixibat
including
pivotal
program
biliary
atresia
planned
pivotal
program
alagille
syndrome
outcomes
trials
albireo
ability
obtain
coverage
pricing
reimbursement
approved
products
united
states
european
union
delays
challenges
recruitment
patients
conduct
phase
trial
pivotal
trials
albireo
critical
accounting
policies
risks
uncertainties
albireo
faces
described
greater
detail
heading
risk
factors
albireo
recent
annual
report
form
subsequent
filings
makes
securities
exchange
commission
result
risks
uncertainties
albireo
faces
results
events
indicated
statement
may
occur
albireo
cautions
place
undue
reliance
statement
addition
statement
press
release
represents
albireo
views
date
press
release
relied
upon
representing
views
subsequent
date
albireo
disclaims
obligation
update
statement
except
required
applicable
law
investor
contact
hans
vitzthum
lifesci
advisors
media
contact
colleen
alabiso
lisa
rivero
albireo
pharma
condensed
consolidated
balance
sheets
thousands
except
share
data
unaudited
september
december
assets
current
assets
cash
cash
equivalents
prepaid
expenses
current
assets
total
current
assets
property
equipment
net
goodwill
assets
total
assets
liabilities
stockholders
equity
current
liabilities
accounts
payable
accrued
expenses
current
liabilities
total
current
liabilities
liability
related
sale
future
royalties
note
payable
net
discount
liabilities
total
liabilities
stockholders
equity
common
stock
par
value
per
share
authorized
september
december
issued
outstanding
september
december
respectively
additional
capital
accumulated
comprehensive
income
accumulated
deficit
total
stockholders
equity
total
liabilities
stockholders
equity
albireo
pharma
condensed
consolidated
statements
operations
thousands
except
share
per
share
data
unaudited
